ACIP votes to expand recommendation for RSV vaccines

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD).

This includes US pharma giant Pfizer’s Abrysvo (respiratory syncytial virus vaccine), which in October 2024, was approved by the US Food and Drug Administration for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.

GSK's (LSE: GSK) Arexvy, which also has FDA approval in that patient population, also stand to benefit from the expanded recommendation.